260MO Long-term patient-reported outcomes in premenopausal women with the hormone receptor-positive breast cancer from ABCSG 22 Registry

The present study investigated the long-term Quality of Life (QoL) and sexual health of premenopausal women, on average 9.5 (range 5-15) years after being diagnosed with a HR-positive breast cancer (BC) registered in the ABCSG 22 registry. Between April 2008 and January 2022, ABCSG collected Patient Reported Outcome (PRO) data from a registry of premenopausal women with HR-positive BC receiving endocrine therapy with tamoxifen and goserelin for five years (± chemotherapy). After a median follow up of 9 (IQR 8-11) years, a cross-sectional PRO assessment targeting QoL, sexual health and fertility issues was conducted at 11 Austrian centres. PRO was assessed using the EORTC QLQ C30, QLQ-BR45, EORTC QLQ-SHQ22, SABIS, MENQOL and fertility questionnaire. All scores are presented descriptively. Differences between subgroups scores and between register scores and values from reference population were evaluated using MANOVA. Overall, 469 women were included; the median age was 46 years at BC diagnosis, 55 years at the time of the PRO assessment. 30% of the women had chemotherapy before the start of hormonal therapy. Compared to the general population, women with a history of BC have statistically significant worse score in the emotional and social functional scales of the EORTC C30 as well as more insomnia, constipation, and more financial difficulties. Interestingly, women with a history of BC reported better global health status than the general population (mean 76.9 vs 71.2). Women who had received prior chemotherapy had a statistically significant worse score in the cognitive (mean 80.6 vs 85.8) and social functioning (mean 73.6 vs 80.2) scales of the EORTC C30, more nausea/vomiting, as well as more financial problems compared to the women with endocrine therapy alone. Analyses regarding sexual health, MENQOL and fertility issues is currently ongoing and will also be presented at the meeting. The long-term side effects of BC therapy and their impact on QoL in premenopausal women are persistent after 10 years of the diagnosis and most pronounced in women who had received additional chemotherapy.